Drug intelligence / Profile preview

Sabin-Based Inactivated Poliomyelitis Vaccine

Development stage: Unknown
Lead developer: Takeda
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV), also known by its code name TAK-195, is a trivalent, inactivated poliomyelitis vaccine developed by Takeda. It is derived from Sabin poliovirus strains (types 1, 2, and 3) and is designed to prevent poliomyelitis. The vaccine is currently undergoing evaluation in a Phase 1/2 clinical trial to assess its safety, tolerability, and immunogenicity in healthy infants, toddlers, and adults. The trial aims to determine the optimal antigen dosage for the vaccine.

Beyond the preview

Go deeper on Sabin-Based Inactivated Poliomyelitis Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sabin-Based Inactivated Poliomyelitis Vaccine.

Explore the full profile